Narwhal Capital Management grew its position in shares of Pfizer, Inc. (NYSE:PFE) by 14.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 160,055 shares of the biopharmaceutical company’s stock after buying an additional 20,025 shares during the quarter. Pfizer accounts for approximately 1.4% of Narwhal Capital Management’s investment portfolio, making the stock its 16th biggest holding. Narwhal Capital Management’s holdings in Pfizer were worth $5,376,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of PFE. Stone House Investment Management LLC raised its holdings in shares of Pfizer by 0.9% in the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the period. Naples Global Advisors LLC raised its holdings in shares of Pfizer by 0.3% in the 1st quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares during the period. Alpha Windward LLC raised its holdings in shares of Pfizer by 1.1% in the 1st quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 89 shares during the period. Asset Planning Services Ltd. raised its holdings in shares of Pfizer by 4.9% in the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares during the period. Finally, SPC Financial Inc. raised its holdings in shares of Pfizer by 1.8% in the 1st quarter. SPC Financial Inc. now owns 7,909 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 138 shares during the period. 69.00% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently commented on PFE shares. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a report on Wednesday, September 13th. Finally, Morgan Stanley reaffirmed a “neutral” rating and issued a $35.00 price target (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $38.04.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/30/pfizer-inc-pfe-holdings-boosted-by-narwhal-capital-management.html.

Shares of Pfizer, Inc. (PFE) traded up 0.28% on Friday, reaching $35.70. 16,003,652 shares of the company traded hands. The stock has a 50-day moving average price of $33.78 and a 200 day moving average price of $33.53. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $36.21. The firm has a market capitalization of $212.32 billion, a P/E ratio of 26.12 and a beta of 1.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the company posted $0.64 earnings per share. Analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.59%. Pfizer’s payout ratio is 94.12%.

In related news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.